Skip to main content
Top
Published in: Dermatology and Therapy 1/2024

Open Access 11-12-2023 | Alopecia Areata | Original Research

Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey

Authors: Kouki Nakamura, Kazumasa Kamei, Jenny Austin, Simran Marwaha, James Piercy, Peter Anderson, Masayo Sakaki-Yumoto, Manabu Ohyama

Published in: Dermatology and Therapy | Issue 1/2024

Login to get access

Abstract

Introduction

Alopecia areata (AA) is characterized by non-scarring scalp and/or body hair loss and can negatively impact patient mental health. Data are limited on the alignment of patient and physician perceptions of AA severity with each other and with Japanese Dermatological Association (JDA) guideline criteria, and of patient-physician alignment on treatment satisfaction. Therefore, we performed analyses to compare JDA severity groupings with patient-physician alignment on disease severity and to explore treatment satisfaction in AA in Japan.

Methods

Data were drawn from the Adelphi AA Disease Specific Programme (DSP)™, a real-world survey of physicians and patients with AA in Japan conducted January-March 2021. Patients and physicians reported patient AA severity as mild, moderate or severe based on their subjective judgement. Patients were then categorized into five hair loss severity groups according to JDA criteria (S1-5), and patient-physician pairs were matched to assess alignment on severity and treatment satisfaction.

Results

Subjective patient- and physician-reported disease severity generally followed JDA severity groupings. The percentage of patient-physician alignment on severity recognition was 76.3% in the overall population. In misaligned pairs, 20.2%, 14.5%, 7.3%, 25.0% and 0.0% of physicians rated disease as more severe than patients in S1, S2, S3, S4 and S5, respectively. Regarding treatment satisfaction, patient-physician alignment was 57.6% in the overall population. In S5, 46.2% of physicians reported being less satisfied than patients. Both physicians and patients cited lack of efficacy as the main reason for dissatisfaction. Of 221 patients, 39.8% and 29.9% were categorized as borderline-abnormal cases for anxiety and depression, respectively.

Conclusions

This study highlights previously unreported patient-physician misalignment on disease severity, level of treatment dissatisfaction and unmet needs due to the lack of effective treatment. Further study on how improvement of the misalignment between physicians and patients could increase both patient and physician satisfaction with treatment and improve the quality of life for patients with AA.
Literature
1.
go back to reference Fukuyama M, Ito T, Ohyama M. Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol. 2022;49(1):19–36.CrossRefPubMed Fukuyama M, Ito T, Ohyama M. Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol. 2022;49(1):19–36.CrossRefPubMed
2.
go back to reference Tsuboi R, Itami S, Manabe S, et al. Japanese Dermatological Association Alopecia areata clinical practice guidelines. Jpn J Dermatol. 2017;127(13):2741–62 (in Japanese). Tsuboi R, Itami S, Manabe S, et al. Japanese Dermatological Association Alopecia areata clinical practice guidelines. Jpn J Dermatol. 2017;127(13):2741–62 (in Japanese).
3.
go back to reference King BA, Senna MM, Ohyama M, et al. Defining severity in alopecia areata: current perspectives and a multidimensional framework. Dermatol Ther (Heidelb). 2022;12(4):825–34.CrossRefPubMed King BA, Senna MM, Ohyama M, et al. Defining severity in alopecia areata: current perspectives and a multidimensional framework. Dermatol Ther (Heidelb). 2022;12(4):825–34.CrossRefPubMed
4.
go back to reference Tan E, Tay YK, Goh CL, Chin GY. The pattern and profile of alopecia areata in Singapore—a study of 219 Asians. Int J Dermatol. 2002;41(11):748–53.CrossRefPubMed Tan E, Tay YK, Goh CL, Chin GY. The pattern and profile of alopecia areata in Singapore—a study of 219 Asians. Int J Dermatol. 2002;41(11):748–53.CrossRefPubMed
5.
go back to reference Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990–2009. J Invest Dermatol. 2014;134(4):1141–2.CrossRefPubMed Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990–2009. J Invest Dermatol. 2014;134(4):1141–2.CrossRefPubMed
6.
go back to reference Mostaghimi A, Gao W, Ray M, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol. 2023;159(4):411–18.CrossRefPubMedPubMedCentral Mostaghimi A, Gao W, Ray M, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol. 2023;159(4):411–18.CrossRefPubMedPubMedCentral
7.
go back to reference Campos-Alberto E, Hirose T, Napatalung L, Ohyama M. Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: a descriptive study using Japan medical data center claims database. J Dermatol. 2023;50(1):37–45.CrossRefPubMed Campos-Alberto E, Hirose T, Napatalung L, Ohyama M. Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: a descriptive study using Japan medical data center claims database. J Dermatol. 2023;50(1):37–45.CrossRefPubMed
8.
go back to reference Edson-Heredia E, Aranishi T, Isaka Y, Anderson P, Marwaha S, Piercy J. Patient and physician perspectives on alopecia areata: A real-world assessment of severity and burden in Japan. J Dermatol. 2022;49(6):575–83.CrossRefPubMedPubMedCentral Edson-Heredia E, Aranishi T, Isaka Y, Anderson P, Marwaha S, Piercy J. Patient and physician perspectives on alopecia areata: A real-world assessment of severity and burden in Japan. J Dermatol. 2022;49(6):575–83.CrossRefPubMedPubMedCentral
9.
go back to reference Reid EE, Haley AC, Borovicka JH, Rademaker A, West DP, Colavincenzo M, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol. 2012;66(3):e97-102.CrossRefPubMed Reid EE, Haley AC, Borovicka JH, Rademaker A, West DP, Colavincenzo M, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol. 2012;66(3):e97-102.CrossRefPubMed
10.
go back to reference Tzur Bitan D, Berzin D, Kridin K, Cohen A. The association between alopecia areata and anxiety, depression, schizophrenia, and bipolar disorder: a population-based study. Arch Dermatol Res. 2022;314(5):463–8.CrossRefPubMed Tzur Bitan D, Berzin D, Kridin K, Cohen A. The association between alopecia areata and anxiety, depression, schizophrenia, and bipolar disorder: a population-based study. Arch Dermatol Res. 2022;314(5):463–8.CrossRefPubMed
11.
go back to reference Rodgers AR. Why finding a treatment for alopecia areata is important: a multifaceted perspective. J Investig Dermatol Symp Proc. 2018;19(1):S51–3.CrossRefPubMed Rodgers AR. Why finding a treatment for alopecia areata is important: a multifaceted perspective. J Investig Dermatol Symp Proc. 2018;19(1):S51–3.CrossRefPubMed
13.
go back to reference King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188(2):218–27.CrossRefPubMed King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188(2):218–27.CrossRefPubMed
15.
go back to reference Kamei K, Hirose T, Yoshii N, Tanaka A. Burden of illness, medication adherence, and unmet medical needs in Japanese patients with atopic dermatitis: a retrospective analysis of a cross-sectional questionnaire survey. J Dermatol. 2021;48(10):1491–8.CrossRefPubMedPubMedCentral Kamei K, Hirose T, Yoshii N, Tanaka A. Burden of illness, medication adherence, and unmet medical needs in Japanese patients with atopic dermatitis: a retrospective analysis of a cross-sectional questionnaire survey. J Dermatol. 2021;48(10):1491–8.CrossRefPubMedPubMedCentral
16.
go back to reference Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes—a means to understand. Curr Med Res Opin. 2008;24(11):3063–72.CrossRefPubMed Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes—a means to understand. Curr Med Res Opin. 2008;24(11):3063–72.CrossRefPubMed
17.
go back to reference Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8): e010352.CrossRefPubMedPubMedCentral Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8): e010352.CrossRefPubMedPubMedCentral
18.
go back to reference Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–80.CrossRefPubMedPubMedCentral Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–80.CrossRefPubMedPubMedCentral
20.
go back to reference Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–70.CrossRefPubMed Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–70.CrossRefPubMed
21.
go back to reference Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30(2):231–6(xiii).CrossRefPubMed Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30(2):231–6(xiii).CrossRefPubMed
22.
go back to reference Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2007;127(6):1351–7.CrossRefPubMed Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2007;127(6):1351–7.CrossRefPubMed
23.
go back to reference StataCorp. Stata statistical software: release 17. College Station: StataCorp LLC; 2021. StataCorp. Stata statistical software: release 17. College Station: StataCorp LLC; 2021.
25.
go back to reference Ito T, Kamei K, Yuasa A, et al. Health-related quality of life in patients with alopecia areata: Results of a Japanese survey with norm-based comparisons. J Dermatol. 2022;49(6):584–93.CrossRefPubMedPubMedCentral Ito T, Kamei K, Yuasa A, et al. Health-related quality of life in patients with alopecia areata: Results of a Japanese survey with norm-based comparisons. J Dermatol. 2022;49(6):584–93.CrossRefPubMedPubMedCentral
26.
go back to reference King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359–64.CrossRefPubMed King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359–64.CrossRefPubMed
27.
go back to reference Juarez-Rendon KJ, Rivera Sanchez G, Reyes-Lopez MA, et al. Alopecia areata. Current situation and perspectives. Arch Argent Pediatr. 2017;115(6):e404–11.PubMed Juarez-Rendon KJ, Rivera Sanchez G, Reyes-Lopez MA, et al. Alopecia areata. Current situation and perspectives. Arch Argent Pediatr. 2017;115(6):e404–11.PubMed
28.
go back to reference Gupta AK, Carviel JL, Foley KA, et al. Monotherapy for alopecia areata: a systematic review and network meta-analysis. Skin Appendage Disord. 2019;5(6):331–7.CrossRefPubMedPubMedCentral Gupta AK, Carviel JL, Foley KA, et al. Monotherapy for alopecia areata: a systematic review and network meta-analysis. Skin Appendage Disord. 2019;5(6):331–7.CrossRefPubMedPubMedCentral
29.
go back to reference Yoshimasu T, Furukawa F. Modified immunotherapy for alopecia areata. Autoimmun Rev. 2016;15(7):664–7.CrossRefPubMed Yoshimasu T, Furukawa F. Modified immunotherapy for alopecia areata. Autoimmun Rev. 2016;15(7):664–7.CrossRefPubMed
30.
go back to reference Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–65.CrossRefPubMed Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–65.CrossRefPubMed
31.
go back to reference Igarashi A, Bekker Hansen B, Langer J, et al. Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with type 2 diabetes: a discrete choice experiment. Adv Ther. 2021;38(1):721–38.CrossRefPubMed Igarashi A, Bekker Hansen B, Langer J, et al. Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with type 2 diabetes: a discrete choice experiment. Adv Ther. 2021;38(1):721–38.CrossRefPubMed
32.
go back to reference Barclay N, Tarallo M, Hendrikx T, Marett S. Patient preference for oral versus injectable and intravenous methods of treatment for rheumatoid arthritis. Value Health. 2013;16(7):A568.CrossRef Barclay N, Tarallo M, Hendrikx T, Marett S. Patient preference for oral versus injectable and intravenous methods of treatment for rheumatoid arthritis. Value Health. 2013;16(7):A568.CrossRef
33.
go back to reference DeTora LM, Toroser D, Sykes A, et al. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298–304.CrossRefPubMed DeTora LM, Toroser D, Sykes A, et al. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298–304.CrossRefPubMed
Metadata
Title
Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey
Authors
Kouki Nakamura
Kazumasa Kamei
Jenny Austin
Simran Marwaha
James Piercy
Peter Anderson
Masayo Sakaki-Yumoto
Manabu Ohyama
Publication date
11-12-2023
Publisher
Springer Healthcare
Keyword
Alopecia Areata
Published in
Dermatology and Therapy / Issue 1/2024
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-023-01067-y

Other articles of this Issue 1/2024

Dermatology and Therapy 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.